MedPath

Faecal Microbiota Transplantation in Patients With Microscopic Colitis

Not Applicable
Completed
Conditions
Microscopic Colitis
Interventions
Other: Faecal microbiota transfer (FMT)
Registration Number
NCT03275467
Lead Sponsor
Örebro University, Sweden
Brief Summary

Microscopic colitis (MC) is a disease with chronic inflammation of the colon that is mostly diagnosed in middle-aged or elderly women. Patients suffer from chronic watery diarrhoea, abdominal pain and weight loss. The aetiology of MC is still unknown but it is hypothesized that MC is caused by a deregulated immune response to a luminal agent in predisposed individuals, and an important role of the intestinal microbiota is suggested.

In the current proof-of-concept study, the effect of faecal microbiota transfer (FMT) in 10 MC patients will be evaluated. FMT consists in the infusion of suspended stool from a healthy donor into the intestine of a patient with the aim to restore a disturbed intestinal microbiota.

Detailed Description

This will be an intervention pilot study with a 12-week and an optional 6-months follow-up period. It will be investigated if the infusion of suspended stool from healthy donors improves the symptoms of MC patients by restoring their disturbed intestinal microbiota. This procedure is known as faecal microbiota transplantation (FMT).

MC patients (n=10) will be randomised to receive FMT using stool from one of two healthy donors.

At baseline, blood samples and mucosal biopsies will be obtained from the descending colon. In addition, faecal samples will be collected and patients will complete symptom questionnaires. The first FMT will be administered by colonoscopy, FMT 2-3 by enemas. Faecal samples will be collected and questionnaires will be completed at different time points during the study. The patients will be followed-up at 6 weeks, 8 weeks, 12 weeks and 6 months after receiving FMT 1, however, the follow-up after 6 months will be optional. Additional biopsies from the descending colon and blood samples will be collected 6 weeks after the first FMT.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Faecal microbiota transfer (FMT)Faecal microbiota transfer (FMT)Suspended stool from a healthy donor
Primary Outcome Measures
NameTimeMethod
Proportion of MC patients in remission six weeks after the first FMT.6 weeks

Remission is defined as \<3 stools per day and a mean of less than one watery stool per day.

Secondary Outcome Measures
NameTimeMethod
Changes in faecal and mucosal microbiota compositionfaecal: 6 weeks, 8 weeks, 12 weeks, 6 months; mucosal: 6 weeks

16S rRNA-based next generation sequencing

Changes in subepithelial collagen layer6 weeks

Immunohistochemistry

Changes in gastrointestinal symptom questionnaire scores6 weeks, 8 weeks, 12 weeks, 6 months

GSRS

Changes in general health questionnaire scores6 weeks, 8 weeks, 12 weeks, 6 months

SF-36

Changes in lymphocyte infiltration6 weeks

Immunohistochemistry and flow cytometry

Changes in general health and symptom questionnaire scores6 weeks, 8 weeks, 12 weeks, 6 months

SHS

Changes in quality of life questionnaire scores6 weeks, 8 weeks, 12 weeks, 6 months

EG-5D-5L

Changes in immune cell composition of colonic biopsies6 weeks

Immunohistochemistry and flow cytometry

Changes in number and form of bowel movements6 weeks, 8 weeks, 12 weeks, 6 months

1-week-diaries

Changes in hospital and anxiety depression scores6 weeks, 8 weeks, 12 weeks, 6 months

HADS

Trial Locations

Locations (1)

University Hospital Örebro

🇸🇪

Örebro, Örebro County, Sweden

© Copyright 2025. All Rights Reserved by MedPath